Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bromocriptine-associated ototoxicity.

P L Lanthier, M Y Morgan, J Ballantyne

    The Journal of Laryngology and Otology
    |April 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Why SARS-CoV-2 vaccination still matters in Africa.

    QJM : monthly journal of the Association of Physicians·2022
    Same author

    Societal reopening after the COVID-19 pandemic.

    Public health·2021
    Same author

    Assigning forensic body fluids to donors in mixed body fluids by targeted RNA/DNA deep sequencing of coding region SNPs.

    International journal of legal medicine·2020
    Same author

    Body fluid identification and assignment to donors using a targeted mRNA massively parallel sequencing approach - results of a second EUROFORGEN / EDNAP collaborative exercise.

    Forensic science international. Genetics·2019
    Same author

    The appropriateness of current UK training in acute internal medicine.

    Acute medicine·2019
    Same author

    Messenger RNA biomarker signatures for forensic body fluid identification revealed by targeted RNA sequencing.

    Forensic science international. Genetics·2018

    Bromocriptine treatment for hepatic encephalopathy may cause hearing loss. Reducing the bromocriptine dose improved hearing, suggesting reversible drug-induced ototoxicity.

    Area of Science:

    • Neurology
    • Ototoxicology

    Background:

    • Chronic hepatic encephalopathy (CHE) management often involves medications like bromocriptine.
    • Bromocriptine is a dopamine agonist used in various neurological and endocrine conditions.

    Observation:

    • Three patients with CHE receiving bromocriptine presented with audiometric findings of bilateral sensorineural hearing loss.
    • This hearing impairment was objectively measured through audiometry.

    Findings:

    • A reduction in bromocriptine dosage led to audibly and measurably improved hearing in all three affected patients.
    • The observed hearing improvement suggests a direct link between bromocriptine and ototoxicity.

    Implications:

    • Bromocriptine may be an ototoxic agent, potentially causing reversible sensorineural hearing loss.

    Related Experiment Videos

  • Clinicians should consider audiometric monitoring in patients on bromocriptine, especially those with CHE.
  • Further research is warranted to elucidate the mechanism of bromocriptine-induced ototoxicity.